Screener
Avalo Therapeutics AVTX Business Segments — Total stock-based compensation
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AllocatedShareBasedCompensationExpense.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Clinical expenses | 3,712 | 7,215 | 9,344 | 11,065 |
| CMC expenses | 5,068 | 3,266 | 9,194 | 5,245 |
| License and milestone expenses | 10,000 | — | 10,000 | — |
| Internal expenses: | ||||
| Salaries, benefits and related costs | 2,630 | 2,181 | 5,216 | 4,030 |
| Stock-based compensation expense | 1,680 | 1,116 | 2,923 | 2,418 |
| Other | 79 | 117 | 149 | 175 |
| $23,418 | $14,074 | $37,466 | $23,195 |
Item 1. Financial Statements.
FAQ
- What is Avalo Therapeutics's business segments — total stock-based compensation?
- Avalo Therapeutics (AVTX) reported business segments — total stock-based compensation of $1.68M in Q2 2026.
- How has Avalo Therapeutics's business segments — total stock-based compensation changed year-over-year?
- Avalo Therapeutics's business segments — total stock-based compensation increased by 50.5% year-over-year, from $1.12M to $1.68M.
- What is the long-term trend for Avalo Therapeutics's business segments — total stock-based compensation?
- Over 2 years (2023 to 2025), Avalo Therapeutics's business segments — total stock-based compensation has grown at a 113.2% compound annual growth rate (CAGR), from $1.32M to $5.99M.
- What does business segments — total stock-based compensation mean?
- Represents the non-cash expense recognized for equity-based awards granted to employees and consultants within the segment. This metric highlights the company's strategy for talent retention and alignment of employee interests with shareholder value. It is a key component of total compensation that does not impact immediate cash liquidity.
Ask your AI about Avalo Therapeutics's business segments — total stock-based compensation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude